---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022361"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:18:47.587520+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncotelic secures $560K convertible note from Mast Hill; enters $25M equity purchase agreement

## Summary
- Issued $560,000 convertible promissory note to Mast Hill Fund, 10% OID, 10% interest, convertible at $0.07/share.
- Note warrants issued for 2,000,000 shares at $0.15 exercise price; note secured against most company assets.
- Also entered $25M equity purchase agreement with Mast Hill; issued warrants for 3,350,000 shares.
- Equity purchase price set at 97% of market price or 102% of market alternative price; commitment period up to 24 months.
- Proceeds from note for general working capital; registration rights agreements filed for resale of underlying shares.

## SEC filing metadata
- accession: 0001641172-25-022361
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000164117225022361/0001641172-25-022361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000164117225022361/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022361
- JSON: https://secwatch.observer/filing/0001641172-25-022361.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022361.txt

## Key facts
- Debt Financings
  Oncotelic Therapeutics, Inc. incurred convertible notes of $560,000 with Mast Hill Fund, LP at 10% per annum maturing earlier of (a) one-year anniversary of the date of the 2025 Mast Hill Purchase Agreement, or (b) acceleration by Mast Hill upon Event of Default, or (c) on prep.
  - Instrument: convertible notes
  - Principal: $560,000
  - Counterparty: Mast Hill Fund, LP
  - Rate: 10% per annum
  - Maturity: earlier of (a) one-year anniversary of the date of the 2025 Mast Hill Purchase Agreement, or (b) acceleration by Mast Hill upon Event of Default, or (c) on prep
  - Event: incurrence
  source text: On July 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2025 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $560,000 (the “ 2025 Mast Hill Note ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000164117225022361/0001641172-25-022361-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.